Perrigo receives FDA approval for generic version of Extina foam

On Tuesday, drugmaker Perrigo Co. said that the generic version of Extina foam, a treatment for skin disease, has been approved by the Food and Drug Administration.

Extina foam is used to treat a skin condition called seborrheic dermatitis that is characterized by scaly or flaky skin. The condition can occur anywhere on the body, although it mostly affects the scalp
Extina foam has annual sales of $10 million. The generic is already being shipped by the company based in Allegan, Mich.
In Tuesday morning trading, Perrigo shares jumped $2.44, or 2.6 percent, to $96.05.